### 1. Summary of Income Statement

<table>
<thead>
<tr>
<th>FY2013</th>
<th>FY2014</th>
<th>Increase (Decrease)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Sales</td>
<td>1,566.0</td>
<td>1,550.1</td>
</tr>
<tr>
<td>Operating income</td>
<td>24.9</td>
<td>42.0</td>
</tr>
<tr>
<td>Ordinary income</td>
<td>22.5</td>
<td>44.4</td>
</tr>
<tr>
<td>Net income (loss)</td>
<td>(25.1)</td>
<td>17.3</td>
</tr>
<tr>
<td>Comprehensive income</td>
<td>10.2</td>
<td>66.2</td>
</tr>
</tbody>
</table>

### 2. Net Sales and Operating Income (Loss) (by business segment)

#### Net Sales

<table>
<thead>
<tr>
<th>FY2013</th>
<th>FY2014</th>
<th>Increase (Decr.)</th>
<th>Breakdown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Functional Chemicals</td>
<td>190.4</td>
<td>219.0</td>
<td>28.6</td>
</tr>
<tr>
<td>Functional Polymeric Materials</td>
<td>176.7</td>
<td>174.5</td>
<td>(2.2)</td>
</tr>
<tr>
<td>Polyurethane</td>
<td>163.8</td>
<td>154.8</td>
<td>(9.0)</td>
</tr>
<tr>
<td>Basic Chemicals</td>
<td>376.2</td>
<td>311.2</td>
<td>(65.0)</td>
</tr>
<tr>
<td>Petrochemicals</td>
<td>552.4</td>
<td>576.8</td>
<td>24.4</td>
</tr>
<tr>
<td>Films and Sheets</td>
<td>79.9</td>
<td>82.7</td>
<td>2.8</td>
</tr>
<tr>
<td>Others</td>
<td>26.6</td>
<td>31.1</td>
<td>4.5</td>
</tr>
<tr>
<td>Total</td>
<td>1,566.0</td>
<td>1,550.1</td>
<td>(15.9)</td>
</tr>
</tbody>
</table>

#### Operating Income (Loss)

<table>
<thead>
<tr>
<th>FY2013</th>
<th>FY2014</th>
<th>Increase (Decr.)</th>
<th>Breakdown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Functional Chemicals</td>
<td>15.0</td>
<td>14.6</td>
<td>(0.4)</td>
</tr>
<tr>
<td>Functional Polymeric Materials</td>
<td>11.9</td>
<td>18.9</td>
<td>7.0</td>
</tr>
<tr>
<td>Polyurethane</td>
<td>(5.2)</td>
<td>(3.5)</td>
<td>1.7</td>
</tr>
<tr>
<td>Basic Chemicals</td>
<td>(17.4)</td>
<td>(7.4)</td>
<td>10.0</td>
</tr>
<tr>
<td>Petrochemicals</td>
<td>25.3</td>
<td>20.9</td>
<td>(4.4)</td>
</tr>
<tr>
<td>Films and Sheets</td>
<td>0.9</td>
<td>3.7</td>
<td>2.8</td>
</tr>
<tr>
<td>Others</td>
<td>(0.6)</td>
<td>0.8</td>
<td>1.4</td>
</tr>
<tr>
<td>Adjustment</td>
<td>(5.0)</td>
<td>(6.0)</td>
<td>(1.0)</td>
</tr>
<tr>
<td>Total</td>
<td>24.9</td>
<td>42.0</td>
<td>17.1</td>
</tr>
</tbody>
</table>

※ Price includes both selling and purchasing price variances.

### 3. Extraordinary Gains and Losses

<table>
<thead>
<tr>
<th>FY2013</th>
<th>FY2014</th>
<th>Increase (Decrease)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gain on sales of fixed assets</td>
<td>2.5</td>
<td>2.3</td>
</tr>
<tr>
<td>Loss on sales and disposal of fixed assets</td>
<td>(2.3)</td>
<td>(4.5)</td>
</tr>
<tr>
<td>Loss on impairment</td>
<td>(0.5)</td>
<td>(5.3)</td>
</tr>
<tr>
<td>Insurance income</td>
<td>4.1</td>
<td>-</td>
</tr>
<tr>
<td>Business structure improvement expenses</td>
<td>(36.8)</td>
<td>-</td>
</tr>
<tr>
<td>Others</td>
<td>-</td>
<td>(1.1)</td>
</tr>
<tr>
<td>Total</td>
<td>(33.0)</td>
<td>(8.6)</td>
</tr>
</tbody>
</table>

### Outlook for FY2015

<table>
<thead>
<tr>
<th>Interim</th>
<th>Full Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Sales</td>
<td>700.0</td>
</tr>
<tr>
<td>Operating income</td>
<td>18.0</td>
</tr>
<tr>
<td>Ordinary income</td>
<td>14.0</td>
</tr>
<tr>
<td>Net income (loss)</td>
<td>5.0</td>
</tr>
</tbody>
</table>

May 12, 2015
Mitsui Chemicals, Inc.
### 4. Summary of Balance Sheet

<table>
<thead>
<tr>
<th></th>
<th>FY2013</th>
<th>FY2014</th>
<th>Increase (Decrease)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current assets</td>
<td>777.1</td>
<td>731.7</td>
<td>(45.4)</td>
</tr>
<tr>
<td>Tangible fixed assets</td>
<td>425.8</td>
<td>433.6</td>
<td>7.8</td>
</tr>
<tr>
<td>Intangible fixed assets</td>
<td>72.2</td>
<td>72.8</td>
<td>0.6</td>
</tr>
<tr>
<td>Investments and others</td>
<td>157.1</td>
<td>173.7</td>
<td>16.6</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>1,432.2</td>
<td>1,411.8</td>
<td>(20.4)</td>
</tr>
<tr>
<td><strong>Liabilities and Net assets</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest-bearing liabilities</td>
<td>581.3</td>
<td>548.7</td>
<td>(32.6)</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>441.3</td>
<td>391.8</td>
<td>(50.5)</td>
</tr>
<tr>
<td>Shareholders' equity</td>
<td>352.8</td>
<td>406.2</td>
<td>53.4</td>
</tr>
<tr>
<td>Minority interest</td>
<td>56.8</td>
<td>65.1</td>
<td>8.3</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>1,432.2</td>
<td>1,411.8</td>
<td>(20.4)</td>
</tr>
</tbody>
</table>

### 5. Summary of Cash Flow

<table>
<thead>
<tr>
<th></th>
<th>FY2013</th>
<th>FY2014</th>
<th>Increase (Decrease)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities</strong></td>
<td>43.5</td>
<td>58.3</td>
<td>14.8</td>
</tr>
<tr>
<td><strong>Free cash flows</strong></td>
<td>(89.8)</td>
<td>(35.0)</td>
<td>54.8</td>
</tr>
<tr>
<td><strong>Cash flows from financing activities</strong></td>
<td>66.9</td>
<td>46.6</td>
<td>(113.5)</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td>5.6</td>
<td>2.7</td>
<td>(2.9)</td>
</tr>
<tr>
<td><strong>Net incr.(decr.) in cash and cash equivalents</strong></td>
<td>26.2</td>
<td>(20.6)</td>
<td>(46.8)</td>
</tr>
<tr>
<td><strong>Cash and cash equivalents at the end of year</strong></td>
<td>71.2</td>
<td>50.6</td>
<td>(20.6)</td>
</tr>
</tbody>
</table>

### 6. Accounting Fundamentals

<table>
<thead>
<tr>
<th></th>
<th>FY2013</th>
<th>FY2014</th>
<th>Increase (Decrease)</th>
</tr>
</thead>
<tbody>
<tr>
<td>R &amp; D expenses</td>
<td>¥ Billions</td>
<td>33.6</td>
<td>32.5</td>
</tr>
<tr>
<td>Depreciation &amp; amortization</td>
<td>¥ Billions</td>
<td>48.1</td>
<td>48.2</td>
</tr>
<tr>
<td>Capital expenditures</td>
<td>¥ Billions</td>
<td>113.2</td>
<td>47.5</td>
</tr>
<tr>
<td>Financing incomes &amp; expenses</td>
<td>¥ Billions</td>
<td>53.8</td>
<td>43.1</td>
</tr>
<tr>
<td>Interest-bearing liabilities</td>
<td>¥ Billions</td>
<td>(3.3)</td>
<td>(2.3)</td>
</tr>
<tr>
<td><strong>Net D/E Ratio</strong></td>
<td>1.44</td>
<td>1.22</td>
<td>(0.22)</td>
</tr>
<tr>
<td>Number of employees</td>
<td>person</td>
<td>14,271</td>
<td>14,363</td>
</tr>
<tr>
<td>Exchange rate</td>
<td>Yen / US$</td>
<td>100</td>
<td>110</td>
</tr>
<tr>
<td>Domestic standard naphtha price</td>
<td>Yen / KL</td>
<td>67,300</td>
<td>63,500</td>
</tr>
</tbody>
</table>

### 7. Scope of Consolidation and Equity Method

<table>
<thead>
<tr>
<th></th>
<th>As of Mar. 31, 2014</th>
<th>As of Mar. 31, 2015</th>
<th>Increase (Decrease)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Consolidated subsidiaries</strong></td>
<td>97</td>
<td>100</td>
<td>3</td>
</tr>
<tr>
<td><strong>Non-consolidated subsidiaries and affiliates</strong></td>
<td>38</td>
<td>37</td>
<td>(1)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>135</td>
<td>137</td>
<td>2</td>
</tr>
</tbody>
</table>

### 8. Topics
- Acquisition of US Corning "SunSensors®" Photochromic Lens Material  (May 2014)
- Acquisition of E.G.S., Srl, a 3D scanner & CAD software company for dental materials in Italy (July 2014)
- Acquisition of Kyowa Industrial Co., Ltd, a mold manufacturer with superior planning and prototyping capabilities (September 2014)
- Commercial operations at "Shanghai Sinopec Mitsui Elastomers, Co., Ltd." new EPT production facility in China (75,000 tons/annum) (December 2014)
• Commercial operations at “Shanghai Sinopec Mitsui Chemical, Co., Ltd.” new phenols plant in China (Phenol: 250,000 tons/annum, Acetone: 150,000 tons/annum) (December 2014)
• Joint venture agreement between Mitsui Chemicals and SKC in polyurethane material business (December 2014)
• Commercial operations of new functional composites production facilities (“Mitsui Chemicals Functional Composites (Shanghai) Co., Ltd.”, MILASTOMER™, ADMER”) in China (March 2015)
• Acquisition of oral medical equipment manufacturer Respire Medical Holdings., LLC in U.S. (March 2015)
• Withdraw from Keiyo Ethylene Co., Ltd (March 2015)

9. Net Sales and Operating Income (Loss) (by new business segment)

<table>
<thead>
<tr>
<th>Segment</th>
<th>FY2014 Interim</th>
<th>FY2014 Full Year</th>
<th>FY2015 Outlook Interim</th>
<th>FY2015 Outlook Full Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare</td>
<td>71.0</td>
<td>144.5</td>
<td>84.0</td>
<td>158.0</td>
</tr>
<tr>
<td>Functional Polymeric Materials</td>
<td>85.7</td>
<td>174.5</td>
<td>89.0</td>
<td>176.0</td>
</tr>
<tr>
<td>Polyurethane</td>
<td>75.0</td>
<td>154.8</td>
<td>65.0</td>
<td>118.0</td>
</tr>
<tr>
<td>Basic Chemicals</td>
<td>171.8</td>
<td>324.5</td>
<td>147.0</td>
<td>293.0</td>
</tr>
<tr>
<td>Petrochemicals</td>
<td>294.0</td>
<td>584.4</td>
<td>233.0</td>
<td>492.0</td>
</tr>
<tr>
<td>Food &amp; Packaging</td>
<td>61.4</td>
<td>129.2</td>
<td>62.0</td>
<td>133.0</td>
</tr>
<tr>
<td>Others</td>
<td>17.1</td>
<td>38.2</td>
<td>20.0</td>
<td>40.0</td>
</tr>
<tr>
<td>Total</td>
<td>776.0</td>
<td>1,550.1</td>
<td>700.0</td>
<td>1,410.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Segment</th>
<th>FY2014 Interim</th>
<th>FY2014 Full Year</th>
<th>FY2015 Outlook Interim</th>
<th>FY2015 Outlook Full Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare</td>
<td>4.7</td>
<td>9.5</td>
<td>5.5</td>
<td>12.0</td>
</tr>
<tr>
<td>Functional Polymeric Materials</td>
<td>7.1</td>
<td>18.7</td>
<td>10.0</td>
<td>19.5</td>
</tr>
<tr>
<td>Polyurethane</td>
<td>(3.5)</td>
<td>(3.5)</td>
<td>(1.5)</td>
<td>(1.5)</td>
</tr>
<tr>
<td>Basic Chemicals</td>
<td>(5.1)</td>
<td>(8.5)</td>
<td>(2.5)</td>
<td>(2.5)</td>
</tr>
<tr>
<td>Petrochemicals</td>
<td>12.5</td>
<td>21.6</td>
<td>6.0</td>
<td>20.5</td>
</tr>
<tr>
<td>Food &amp; Packaging</td>
<td>5.3</td>
<td>9.1</td>
<td>4.5</td>
<td>10.0</td>
</tr>
<tr>
<td>Others</td>
<td>0.4</td>
<td>0.9</td>
<td>0.0</td>
<td>0.5</td>
</tr>
<tr>
<td>Adjustment</td>
<td>(2.8)</td>
<td>(6.0)</td>
<td>(4.0)</td>
<td>(6.5)</td>
</tr>
<tr>
<td>Total</td>
<td>18.6</td>
<td>42.0</td>
<td>18.0</td>
<td>52.0</td>
</tr>
</tbody>
</table>

* Changes in Reported Segments classification methods
On Apr. 1 2015, to accelerate the business strategy of 2014 Mid-Term Business Plan, Strategy of New Business and New Products Creation, and the Business Support Strategy, the Mitsui Chemicals Group changed its organizational structure. Therefore, segmentation of some particular businesses is changed.

From the Functional Chemicals segment, the Fine & Performance Chemicals business is changed to the Basic Chemicals segment, the License business is changed to the Petrochemicals segment, the Healthcare business and nonwoven fabric business is categorized to the Healthcare segment.

Agrochemicals business, which was in the Functional Chemicals segment, is combined with the Films & Sheets segment. The new segment became the Food & Packaging segment.

The amounts of FY2014 are approximate estimates to compare with FY2015 forecast. They are unaudited.

10. Dividends

<table>
<thead>
<tr>
<th>FY2013 Result</th>
<th>FY2014 Result</th>
<th>FY2015 Outlook</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.00</td>
<td>5.00</td>
<td>6.00</td>
</tr>
</tbody>
</table>

11. Number of shares outstanding (common stock)

<table>
<thead>
<tr>
<th>FY2013</th>
<th>FY2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of shares outstanding at term-end (including treasury stock)</td>
<td>1,022,020,076</td>
</tr>
<tr>
<td>Number of shares of treasury stock at term-end</td>
<td>20,788,036</td>
</tr>
<tr>
<td>Average number of shares</td>
<td>1,001,447,485</td>
</tr>
</tbody>
</table>
1. Operating Results

(1) Overview

In the fiscal period under review (the twelve-month period from Apr 1, 2014 to Mar 31, 2015, hereafter “fiscal 2014”), while economic conditions improved in the United States and minor improvement was seen in Europe, economic growth slowed in China and emerging markets.

In Japan, recovery from the contraction following the surge in demand ahead of the consumption tax hike was impacted by unseasonal weather in summer resulting in lackluster economic recovery during the period under review.

In the industry, although there were pullbacks in purchasing due to lowered crude oil prices in later half of the period, operating rates at production facilities for certain products continued at high levels. In general, conditions were seen to improve.

Under these circumstances, the Mitsui Chemicals Group (hereafter “the Group”), which started its 2014 Mid-Term Business Plan in fiscal 2014, continued to focus on its 3 targeted growth driving domains of Mobility, Healthcare and, Food & Packaging.

In the Mobility domain, the Group aims to strengthen its business by providing solutions to eco-friendly automobile industry. The Group will fully utilize its resources, mainly with the PP compounds, elastomers and a broad resins product portfolio and the strong customer base.

In the Healthcare domain, the Group established a new brand “Whole You™” in the United States, to explore new business opportunities and promote its healthcare products to patients and customers, in addition to continuing to expand its core business in ophthalmic lens materials, dental materials and nonwoven fabrics products.

In the Food & Packaging domain, to accelerate its global expansion of agrochemicals and packaging products with a focus on growing Asian markets, the Group will bolster marketing activities and target business expansion.

In the commodity chemicals, mostly the Petrochemicals and the Basic Chemicals, which support a wide variety of industries and society, the Group will continue to pursue optimization of production sites and business restructuring of volatile market products such as polyurethane materials, phenols and PTA.

The Group reported the following operating results for fiscal 2014.

<table>
<thead>
<tr>
<th></th>
<th>Net Sales</th>
<th>Operating Income</th>
<th>Ordinary Income</th>
<th>Net Income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fiscal 2014</td>
<td>1,550.1</td>
<td>42.0</td>
<td>44.4</td>
<td>17.3</td>
</tr>
<tr>
<td>Previous fiscal year</td>
<td>1,566.0</td>
<td>24.9</td>
<td>22.5</td>
<td>(25.1)</td>
</tr>
<tr>
<td>Change</td>
<td>(15.9)</td>
<td>17.1</td>
<td>21.9</td>
<td>42.4</td>
</tr>
<tr>
<td>Change (%)</td>
<td>(1.0)</td>
<td>68.8</td>
<td>97.2</td>
<td>-</td>
</tr>
</tbody>
</table>

Net Sales decreased 15.9 billion yen, or 1.0%, compared with the previous fiscal year to 1,550.1 billion yen. This was mainly attributable to 32.8 billion yen increase in sales prices and 48.7 billion yen decrease in sales volume. Sales prices were higher because of the rise in naphtha, other raw materials and fuel prices as well as the impact of weaker yen. In the factor of sales volume, the improvement of capacity utilization in the Petrochemicals segment and the increased sales of the dental materials business in the Functional Chemicals segment, were set off by the impact of 15-month results of some subsidiaries due to the unification of accounting periods in previous fiscal year and the decrease in the Basic Chemicals segment, because some consolidated subsidiaries were changed to equity method.
Net sales overseas were 686.1 billion yen, a decrease of 0.3% compared with the previous fiscal year to 44.3% in the total net sales.

**Operating income** was 42.0 billion yen, an increase of 17.1 billion yen or 68.8% year on year. This result was due to improvement in terms of trade in the Basic Chemicals and Functional Polymeric Materials segments.

**Ordinary income** was 44.4 billion yen, increased 21.9 billion yen or 97.2% year on year. This result largely reflected an increase in operating income.

**Extraordinary income and loss** improved by 24.4 billion yen year on year to 8.6 billion yen loss, due to a drop in the business restructuring expenses booked to the Polyurethane business and the Phenol business in the previous fiscal year.

As a result of the aforementioned factors, **net income and loss before income taxes and minority interests** amounted to an income of 35.8 billion yen, an improvement of 46.3 billion yen, year on year.

**Net income and loss** after accounting for income taxes and minority interests was a net income of 17.3 billion yen, a growth of 42.4 billion yen, compared with the previous fiscal year. Net income per share for the period was 17.24 yen.

(2) **Results by Business Segment**

The status of each segment during fiscal 2014 is as follows.

**Functional Chemicals**
Net sales increased 28.6 billion yen year on year to 219.0 billion yen and comprised 14% of total sales. On the other hand, operating income fell 0.4 billion yen compared with the previous fiscal year to 14.6 billion yen mainly due to increased fixed costs despite expanded sales.

The **dental materials** business contributed to sales growth while incurring amortization of goodwill expenses.

Sales were favorable for ophthalmic lens materials in **healthcare materials** and nonwoven fabrics in **hygiene materials** as well as for **agrochemicals**, primarily as a result of higher overseas demand.

**Functional Polymeric Materials**
Net sales decreased 2.2 billion yen compared with the previous fiscal year to 174.5 billion yen and comprised 11% of total sales. On the other hand, operating income grew 7.0 billion yen to 18.9 billion yen year on year. The income growth was due to the impact of weaker yen and the Group’s prompt response to increased market demand, despite a drop in income from 15-month results of some subsidiaries consolidated in the previous fiscal year due to unification of accounting periods.

Profits increased for **elastomers**, which are primarily used in automotive components and resin modifiers, mainly from expanding demand in the global automobile market and a weaker yen.

Profits also increased for **performance compounds** thanks to the impact of weaker yen, expanded demand for automotive applications, primarily in North America and Asia.
Profits from **specialty polyolefins** were boosted by the weaker yen impact and quick response to demand for IT-related products, especially in smartphones.

**Polyurethane**

Net sales decreased 9.0 billion yen year on year to 154.8 billion yen. It comprised 10% of total sales. On the other hand, operating loss improved 1.7 billion yen year on year to 3.5 billion yen. Overseas markets for polyurethane materials declined but were positively impacted by a weaker yen.

In **coating materials**, profit expanded as overseas demand increased. On the flipside, harsh conditions and weak demand continued for **polyurethane materials**, which are used mainly in furniture manufacturing.

**Basic Chemicals**

Net sales decreased 65.0 billion yen year on year to 311.2 billion yen and accounted for 20% of total sales. On the other hand, operating loss improved by 10.0 billion yen year on year, to 7.4 billion yen. This was mainly attributed to favorable trading terms, which were caused by industrial-wide phenols production facilities’ periodic maintenance by Asian competitors, and the result of business structure improvement.

Conditions for **phenols** continue to be difficult. Although the business environment improved in comparison with the previous fiscal year as a result of delays in competitor plant start-ups, conditions continued to be unfavorable.

Conditions for **PTA** remained severe mainly due to market stagnation in China.

**Petrochemicals**

Net sales increased 24.4 billion yen compared with the previous fiscal year to 576.8 billion yen. This comprised 37% of total sales. On the other hand, operating income decreased 4.4 billion yen year on year to 20.9 billion yen primarily due to inventory valuation loss caused by a sudden drop in oil prices.

Operating rate of naphtha crackers grew compared to the previous fiscal year. Profits expanded for overseas businesses mainly due to the increased production of automobiles in North and Central America.

**Films and Sheets**

Net sales grew 2.8 billion yen compared with the previous fiscal year to 82.7 billion yen and comprised 6% of total sales. Operating income increased 2.8 billion yen to 3.7 billion yen year on year due to increased sales of high-value-added products, a weak yen, and cost-cutting efforts.

In **packaging films**, despite a sales price revision implemented from the beginning of the fiscal year, profits decreased due to higher prices of raw materials, contracted demand following a surge ahead of the consumption tax hike and sales price revision and decreased demand caused by unseasonal weather in summer.

In **industrial films** for electronic and information applications, profits rose due to increased demand related to high-value-added products, especially smartphones.

In **encapsulant sheets** used in solar modules, profits improved due to efforts to expand sales by new products and cost cuts despite sales prices declines from fierce competition in an ongoing severe business environment.

**Others**

Net sales increased 4.5 billion yen to 31.1 billion yen, comprised 2% of total sales.
Operating profit improved by 1.4 billion yen year on year to an income of 0.8 billion yen.

(3) Outlook for Fiscal 2015 (Year Ending March 31, 2016)
(Overall of Financial Outlook for Fiscal 2015)
The fiscal 2015 global economy is predicted to gradually recover, especially in the United States and other developed countries, while the pace of economic growth in China continues to slow down.

The Japanese economy is expected to grow as a result of the delay in the proposed consumption tax hike. Individual consumption is expected to recover against a backdrop of improved employment and increased income.

Although prospects remain unclear, the chemical industry is slated for recovery due to increasing demand in line with global economic recovery.

The effect of business restructuring of volatile market products and steady business expansion in growth driving domains, leads the Mitsui Chemicals Group to forecast its business performance and earnings growth for fiscal 2015 as follows.

<table>
<thead>
<tr>
<th></th>
<th>Net Sales</th>
<th>Operating Income</th>
<th>Ordinary Income</th>
<th>Net Income</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2015</td>
<td>1,410.0</td>
<td>52.0</td>
<td>47.0</td>
<td>25.0</td>
</tr>
<tr>
<td>FY2014</td>
<td>1,550.1</td>
<td>42.0</td>
<td>44.4</td>
<td>17.3</td>
</tr>
<tr>
<td>Difference</td>
<td>(140.1)</td>
<td>10.0</td>
<td>2.6</td>
<td>7.7</td>
</tr>
<tr>
<td>Ratio (%)</td>
<td>(9.0)</td>
<td>23.7</td>
<td>5.8</td>
<td>44.8</td>
</tr>
</tbody>
</table>

Outlook above are based on the following assumptions:

a) Exchange rate for the full year is 120 yen/US$

b) Average price of domestic naphtha is 50,000 yen /kl

On Apr. 1 2015, to accelerate the business strategy of 2014 Mid-Term Business Plan, Strategy of New Business and New Products Creation, and the Business Support Strategy, the Mitsui Chemicals Group changed its organizational structure. Therefore, segmentation of some particular businesses is changed.

From the Functional Chemicals segment, the Fine & Performance Chemicals business is changed to the Basic Chemicals segment, the License business is changed to the Petrochemicals segment, the Healthcare business and nonwoven fabric business is categorized to the Healthcare segment.

Agrochemicals business, which was in the Functional Chemicals segment, is combined with the Films & Sheets segment. The new segment became the Food & Packaging segment.

The amounts of FY2014 are approximate estimates to compare with FY2015 forecast.
(Outlook by FY2015 Business Segment)
Outlook by FY2015 business segment is as follows. The amounts of FY2014 are summarized by segments of FY2015.

(Billions of Yen)

<table>
<thead>
<tr>
<th></th>
<th>Healthcare</th>
<th>Functional Polymeric Materials</th>
<th>Polyurethane</th>
<th>Basic Chemicals</th>
<th>Petrochemicals</th>
<th>Food &amp; Packaging</th>
<th>Others</th>
<th>Adjustment</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2015</td>
<td>158.0</td>
<td>176.0</td>
<td>118.0</td>
<td>293.0</td>
<td>492.0</td>
<td>133.0</td>
<td>40.0</td>
<td>–</td>
<td>1,410.0</td>
</tr>
<tr>
<td>FY2014</td>
<td>144.5</td>
<td>174.5</td>
<td>154.8</td>
<td>324.5</td>
<td>584.4</td>
<td>129.2</td>
<td>38.2</td>
<td>–</td>
<td>1,550.1</td>
</tr>
<tr>
<td>Difference</td>
<td>13.5</td>
<td>1.5</td>
<td>(36.8)</td>
<td>(31.5)</td>
<td>(92.4)</td>
<td>3.8</td>
<td>1.8</td>
<td>–</td>
<td>(140.1)</td>
</tr>
<tr>
<td>Ratio(%)</td>
<td>9.3</td>
<td>0.9</td>
<td>(23.8)</td>
<td>(9.7)</td>
<td>(15.8)</td>
<td>3.0</td>
<td>4.7</td>
<td>(9.0)</td>
<td></td>
</tr>
</tbody>
</table>

(Billions of Yen)

<table>
<thead>
<tr>
<th></th>
<th>Healthcare</th>
<th>Functional Polymeric Materials</th>
<th>Polyurethane</th>
<th>Basic Chemicals</th>
<th>Petrochemicals</th>
<th>Food &amp; Packaging</th>
<th>Others</th>
<th>Adjustment</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2015</td>
<td>12.0</td>
<td>19.5</td>
<td>(1.5)</td>
<td>(2.5)</td>
<td>20.5</td>
<td>10.0</td>
<td>0.5</td>
<td>(6.5)</td>
<td>52.0</td>
</tr>
<tr>
<td>FY2014</td>
<td>9.5</td>
<td>18.7</td>
<td>(3.5)</td>
<td>(8.3)</td>
<td>21.6</td>
<td>9.1</td>
<td>0.9</td>
<td>(6.0)</td>
<td>42.0</td>
</tr>
<tr>
<td>Difference</td>
<td>2.5</td>
<td>0.8</td>
<td>2.0</td>
<td>5.8</td>
<td>(1.1)</td>
<td>0.9</td>
<td>0.4</td>
<td>(0.5)</td>
<td>10.0</td>
</tr>
<tr>
<td>Ratio(%)</td>
<td>25.8</td>
<td>4.4</td>
<td>–</td>
<td>–</td>
<td>(5.0)</td>
<td>10.0</td>
<td>(43.4)</td>
<td>–</td>
<td>23.7</td>
</tr>
</tbody>
</table>

2. Financial Position

(1) Status of Assets, Liabilities and Net Assets
Total assets at the end of the fiscal year stood at 1,411.8 billion yen, a decrease of 20.4 billion yen compared with the end of the previous fiscal year.

Total liabilities at the end of the fiscal year decreased 82.1 billion yen compared with the previous fiscal year-end to 940.5 billion yen. Interest-bearing debt amounted to 548.7 billion yen, a fall of 32.6 billion yen compared with March 31, 2014. As a result, the interest-bearing debt ratio was 38.9%, a decrease of 1.7 percentage points.

Net assets totaled 471.3 billion yen, an increase of 61.7 billion yen compared with the previous fiscal year-end. The ratio of shareholders’ equity to total assets was 28.8%, up 4.2 percentage point from the previous fiscal year-end.

Accounting for the aforementioned factors, the net debt-equity ratio stood at 1.22 at the end of the fiscal year, down 0.22 point from the previous fiscal year-end.

(2) Cash Flow Status
Cash and cash equivalents (hereafter called “cash”) were down 20.6 billion yen to 50.6 billion yen as of the end of this fiscal year compared with the previous fiscal year-end.

Cash Flows from Operating Activities
Net cash provided by operating activities grew 14.8 billion yen to 58.3 billion yen due to an increase of net income before income tax and minority interests.
Cash Flows from Investing Activities
Net cash used in investing activities decreased 35.0 billion yen compared with the previous fiscal year to 54.8 billion yen due to outflows for the acquisition of the Heraeus Kulzer Dental Business in the previous fiscal year.

Cash Flows from Financing Activities
Net cash used in financing activities was 46.6 billion yen due primarily to repayments of interest-bearing debts.

(3) Trends in Cash Flow Indicators

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Shareholders' Equity Ratio (%)</td>
<td>29.6</td>
<td>29.2</td>
<td>28.2</td>
<td>24.6</td>
<td>28.8</td>
</tr>
<tr>
<td>Shareholders' Equity Ratio on a Market Value Basis (%)</td>
<td>22.7</td>
<td>20.0</td>
<td>15.4</td>
<td>17.7</td>
<td>27.4</td>
</tr>
<tr>
<td>Ratio of Interest-bearing Debt to Cash Flows</td>
<td>6.6</td>
<td>10.7</td>
<td>27.4</td>
<td>13.4</td>
<td>9.4</td>
</tr>
<tr>
<td>Interest Coverage Ratio (Times)</td>
<td>9.5</td>
<td>6.4</td>
<td>2.7</td>
<td>5.6</td>
<td>7.7</td>
</tr>
</tbody>
</table>

Notes:
- Shareholders’ Equity Ratio: Shareholders’ equity to total assets.
- Shareholders’ Equity Ratio on a Market Value Basis: Market capitalization to total assets.
- Interest Coverage Ratio: Cash flows to interest paid.
- Each of the indicators was calculated using consolidated financial figures.
- The market capitalization was calculated by multiplying the closing share price as of the end of the period with the number of shares outstanding (excluding treasury stock).
- Operating cash flow figures have been used for cash flow calculations.
- Interest-bearing debt is the portion of total debt booked on the consolidated balance sheet on which interest is being paid. Interest paid is the amount of interest paid as reported in the consolidated statements of cash flows.


(1) Basic Policy on the Appropriation of Profits
The Group believes that the enhancement of corporate value through business growth and expansion is an important management issue and regards the distribution of profits to shareholders as one of the Group’s most important management policies.

In allocating profits, the Group considers both the need to return earnings to shareholders as well as the need to maintain a level of internal reserves sufficient to fueling and sustaining future growth.

Taking into consideration the consolidated dividend payout ratio and the dividend on equity (DOE) ratio, the Group strives to promote a policy of consistent stable dividends that reflect consolidated earnings results over the medium term. In this context, the Group targets a consolidated dividend payout ratio of 25% or more and DOE of 2% or more.

From an internal reserves perspective, the Group actively engages in investment and
financing to further accelerate growth and expansion while swiftly realizing a robust business portfolio as well as research and development expenditure aimed at creating innovative technologies. To this end, the Group constantly endeavors to improve its business performance and results.

(2) Cash Dividends for Fiscal 2014 and 2015
In current fiscal year, the Group plans to pay a year-end dividend of 3 yen per share. Because the Group paid an interim dividend of 2 yen per share on December 4, 2014, the annual dividend for the fiscal year under review will be 5 yen per share.

Turning to dividends for the fiscal year ending March 31, 2016, the Group plans to pay interim and year-end dividends of 3 yen per share, respectively. The Group therefore plans the annual dividend for the fiscal year to be 6 yen per share.
### 4. Consolidated Balance sheets

<table>
<thead>
<tr>
<th></th>
<th>FY2013 At the end of March 31, 2014</th>
<th>FY2014 At the end of March 31, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and deposits</td>
<td>71,979</td>
<td>52,004</td>
</tr>
<tr>
<td>Notes and accounts receivable-trade</td>
<td>296,492</td>
<td>299,052</td>
</tr>
<tr>
<td>Inventories</td>
<td>301,158</td>
<td>291,295</td>
</tr>
<tr>
<td>Deferred tax assets</td>
<td>9,828</td>
<td>9,118</td>
</tr>
<tr>
<td>Accounts receivable-other</td>
<td>89,677</td>
<td>70,981</td>
</tr>
<tr>
<td>Other</td>
<td>8,653</td>
<td>10,079</td>
</tr>
<tr>
<td>Allowance for doubtful accounts</td>
<td>(772)</td>
<td>(821)</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>777,015</td>
<td>731,708</td>
</tr>
<tr>
<td><strong>Noncurrent assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Property, plant and equipment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buildings and structures</td>
<td>330,822</td>
<td>337,811</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>(221,602)</td>
<td>(229,306)</td>
</tr>
<tr>
<td>Buildings and structures, net</td>
<td>109,220</td>
<td>108,505</td>
</tr>
<tr>
<td>Machinery, equipment and vehicles</td>
<td>1,011,771</td>
<td>1,012,850</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>(885,662)</td>
<td>(888,755)</td>
</tr>
<tr>
<td>Machinery, equipment and vehicles, net</td>
<td>126,109</td>
<td>124,095</td>
</tr>
<tr>
<td>Land</td>
<td>159,674</td>
<td>160,188</td>
</tr>
<tr>
<td>Construction in progress</td>
<td>20,799</td>
<td>28,994</td>
</tr>
<tr>
<td>Other</td>
<td>70,400</td>
<td>73,035</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>(60,362)</td>
<td>(61,188)</td>
</tr>
<tr>
<td>Other, net</td>
<td>10,038</td>
<td>11,847</td>
</tr>
<tr>
<td><strong>Total property, plant and equipment</strong></td>
<td>425,840</td>
<td>433,629</td>
</tr>
<tr>
<td><strong>Intangible assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goodwill</td>
<td>34,935</td>
<td>34,978</td>
</tr>
<tr>
<td>Other</td>
<td>37,275</td>
<td>37,785</td>
</tr>
<tr>
<td><strong>Total intangible assets</strong></td>
<td>72,210</td>
<td>72,763</td>
</tr>
<tr>
<td><strong>Investments and other assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment securities</td>
<td>108,620</td>
<td>109,830</td>
</tr>
<tr>
<td>Net defined benefit asset</td>
<td>13,036</td>
<td>25,170</td>
</tr>
<tr>
<td>Deferred tax assets</td>
<td>5,448</td>
<td>5,853</td>
</tr>
<tr>
<td>Other</td>
<td>30,919</td>
<td>33,706</td>
</tr>
<tr>
<td>Allowance for doubtful accounts</td>
<td>(926)</td>
<td>(869)</td>
</tr>
<tr>
<td><strong>Total investments and other assets</strong></td>
<td>157,097</td>
<td>173,690</td>
</tr>
<tr>
<td><strong>Total noncurrent assets</strong></td>
<td>655,147</td>
<td>680,082</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>1,432,162</td>
<td>1,411,790</td>
</tr>
<tr>
<td>Liabilities</td>
<td>FY2013</td>
<td>FY2014</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td><strong>Current liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notes and accounts payable-trade</td>
<td>219,849</td>
<td>164,193</td>
</tr>
<tr>
<td>Short-term loans payable</td>
<td>121,967</td>
<td>122,062</td>
</tr>
<tr>
<td>Current portion of long-term loans payable</td>
<td>41,188</td>
<td>36,192</td>
</tr>
<tr>
<td>Commercial papers</td>
<td>15,000</td>
<td>—</td>
</tr>
<tr>
<td>Current portion of bonds</td>
<td>13,000</td>
<td>20,142</td>
</tr>
<tr>
<td>Income taxes payable</td>
<td>4,455</td>
<td>4,103</td>
</tr>
<tr>
<td>Provision for directors’ bonuses</td>
<td>42</td>
<td>93</td>
</tr>
<tr>
<td>Provision for repairs</td>
<td>12,324</td>
<td>10,601</td>
</tr>
<tr>
<td>Provision for business structure improvement</td>
<td>2,337</td>
<td>1,290</td>
</tr>
<tr>
<td>Asset retirement obligations</td>
<td>—</td>
<td>25</td>
</tr>
<tr>
<td>Other</td>
<td>76,894</td>
<td>89,798</td>
</tr>
<tr>
<td><strong>Total current liabilities</strong></td>
<td>507,056</td>
<td>448,499</td>
</tr>
<tr>
<td><strong>Noncurrent liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bonds payable</td>
<td>99,000</td>
<td>79,858</td>
</tr>
<tr>
<td>Long-term loans payable</td>
<td>290,595</td>
<td>289,138</td>
</tr>
<tr>
<td>Deferred tax liabilities</td>
<td>22,923</td>
<td>24,421</td>
</tr>
<tr>
<td>Provision for directors’ retirement benefits</td>
<td>295</td>
<td>283</td>
</tr>
<tr>
<td>Provision for repairs</td>
<td>2,227</td>
<td>2,147</td>
</tr>
<tr>
<td>Provision for environmental measures</td>
<td>1,621</td>
<td>956</td>
</tr>
<tr>
<td>Provision for business structure improvement</td>
<td>14,213</td>
<td>10,846</td>
</tr>
<tr>
<td>Net defined benefit liability</td>
<td>58,324</td>
<td>59,193</td>
</tr>
<tr>
<td>Asset retirement obligations</td>
<td>3,770</td>
<td>4,268</td>
</tr>
<tr>
<td>Other</td>
<td>22,491</td>
<td>20,882</td>
</tr>
<tr>
<td><strong>Total noncurrent liabilities</strong></td>
<td>515,459</td>
<td>491,992</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>1,022,515</td>
<td>940,491</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shareholders’ equity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital stock</td>
<td>125,053</td>
<td>125,053</td>
</tr>
<tr>
<td>Capital surplus</td>
<td>91,065</td>
<td>91,065</td>
</tr>
<tr>
<td>Retained earnings</td>
<td>149,287</td>
<td>165,408</td>
</tr>
<tr>
<td>Treasury stock</td>
<td>(14,341)</td>
<td>(14,454)</td>
</tr>
<tr>
<td><strong>Total shareholders’ equity</strong></td>
<td>351,064</td>
<td>367,072</td>
</tr>
<tr>
<td>Accumulated other comprehensive income</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valuation difference on available-for-sale securities</td>
<td>16,678</td>
<td>21,018</td>
</tr>
<tr>
<td>Deferred gains or losses on hedges</td>
<td>(105)</td>
<td>(331)</td>
</tr>
<tr>
<td>Foreign currency translation adjustments</td>
<td>6,551</td>
<td>28,926</td>
</tr>
<tr>
<td>Remeasurements of defined benefit plans</td>
<td>(21,345)</td>
<td>(10,450)</td>
</tr>
<tr>
<td><strong>Total accumulated other comprehensive income</strong></td>
<td>1,779</td>
<td>39,163</td>
</tr>
<tr>
<td>Minority interests</td>
<td>56,804</td>
<td>65,064</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>409,647</td>
<td>471,299</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>1,432,162</td>
<td>1,411,790</td>
</tr>
</tbody>
</table>
5. Consolidated Income Statements and Consolidated Comprehensive Income Statements

(Consolidated Income Statements)

<table>
<thead>
<tr>
<th></th>
<th>FY2013</th>
<th>FY2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>April 1, 2013 to March 31, 2014</td>
<td>April 1, 2014 to March 31, 2015</td>
</tr>
<tr>
<td><strong>Net sales</strong></td>
<td>1,566,046</td>
<td>1,550,076</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>1,353,536</td>
<td>1,308,542</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>212,510</td>
<td>241,534</td>
</tr>
<tr>
<td><strong>Selling, general and administrative expenses</strong></td>
<td>187,611</td>
<td>199,494</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>24,899</td>
<td>42,040</td>
</tr>
<tr>
<td><strong>Non-operating income and expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-operating income</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest income</td>
<td>358</td>
<td>367</td>
</tr>
<tr>
<td>Dividends income</td>
<td>3,724</td>
<td>4,751</td>
</tr>
<tr>
<td>Amortization of negative goodwill</td>
<td>679</td>
<td>23</td>
</tr>
<tr>
<td>Equity in earnings of affiliates</td>
<td>786</td>
<td>-</td>
</tr>
<tr>
<td>Foreign exchange Gains</td>
<td>165</td>
<td>5,147</td>
</tr>
<tr>
<td>Other</td>
<td>4,073</td>
<td>4,485</td>
</tr>
<tr>
<td><strong>Total non-operating income</strong></td>
<td>9,785</td>
<td>14,773</td>
</tr>
<tr>
<td><strong>Non-operating expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest expenses</td>
<td>7,372</td>
<td>7,353</td>
</tr>
<tr>
<td>Loss on suspension of operations</td>
<td>869</td>
<td>1,492</td>
</tr>
<tr>
<td>Equity in earnings of affiliates</td>
<td>-</td>
<td>73</td>
</tr>
<tr>
<td>Other</td>
<td>3,921</td>
<td>3,484</td>
</tr>
<tr>
<td><strong>Total non-operating expenses</strong></td>
<td>12,162</td>
<td>12,402</td>
</tr>
<tr>
<td><strong>Ordinary income</strong></td>
<td>22,522</td>
<td>44,411</td>
</tr>
<tr>
<td><strong>Extraordinary income and loss</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Extraordinary income</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gain on sales of noncurrent assets</td>
<td>128</td>
<td>135</td>
</tr>
<tr>
<td>Gain on sales of investment securities</td>
<td>2,432</td>
<td>2,126</td>
</tr>
<tr>
<td>Insurance income</td>
<td>4,044</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total extraordinary income</strong></td>
<td>6,604</td>
<td>2,261</td>
</tr>
<tr>
<td><strong>Extraordinary loss</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss on disposal of noncurrent assets</td>
<td>5,851</td>
<td>4,446</td>
</tr>
<tr>
<td>Loss on sales of noncurrent assets</td>
<td>17</td>
<td>24</td>
</tr>
<tr>
<td>Impairment loss</td>
<td>4,444</td>
<td>5,278</td>
</tr>
<tr>
<td>Loss on restructuring of subsidiaries and affiliates</td>
<td>2,167</td>
<td>-</td>
</tr>
<tr>
<td>Loss on business withdrawal</td>
<td>1,523</td>
<td>-</td>
</tr>
<tr>
<td>Loss on revision of retirement benefit plan</td>
<td>-</td>
<td>181</td>
</tr>
<tr>
<td>Contract termination Fees</td>
<td>-</td>
<td>903</td>
</tr>
<tr>
<td>Business structure improvement expenses</td>
<td>25,662</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total extraordinary loss</strong></td>
<td>39,664</td>
<td>10,832</td>
</tr>
<tr>
<td><strong>Net Income (loss) before income taxes and minority interests</strong></td>
<td>(10,538)</td>
<td>35,540</td>
</tr>
<tr>
<td><strong>Income taxes—current</strong></td>
<td>10,475</td>
<td>10,402</td>
</tr>
<tr>
<td><strong>Income taxes—deferred</strong></td>
<td>897</td>
<td>1,078</td>
</tr>
<tr>
<td><strong>Total income taxes</strong></td>
<td>11,372</td>
<td>11,480</td>
</tr>
<tr>
<td><strong>Income (loss) before minority interests</strong></td>
<td>(21,910)</td>
<td>24,360</td>
</tr>
<tr>
<td><strong>Minority interests in income</strong></td>
<td>3,228</td>
<td>7,099</td>
</tr>
<tr>
<td><strong>Net income (loss)</strong></td>
<td>(25,138)</td>
<td>17,261</td>
</tr>
</tbody>
</table>
## (Consolidated Comprehensive Income Statements)

### Millions of yen

<table>
<thead>
<tr>
<th></th>
<th>FY2013</th>
<th>FY2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>April 1, 2013 to March 31, 2014</td>
<td>April 1, 2014 to March 31, 2015</td>
</tr>
<tr>
<td>Income before minority interests</td>
<td>(21,910)</td>
<td>24,360</td>
</tr>
<tr>
<td>Other comprehensive income (loss)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valuation difference on available-for-sale securities</td>
<td>3,907</td>
<td>4,644</td>
</tr>
<tr>
<td>Deferred gains or losses on hedges</td>
<td>124</td>
<td>(412)</td>
</tr>
<tr>
<td>Foreign currency translation adjustment</td>
<td>21,892</td>
<td>22,770</td>
</tr>
<tr>
<td>Remeasurements of defined benefit plans</td>
<td>—</td>
<td>10,613</td>
</tr>
<tr>
<td>Post retirement liability adjustments for foreign consolidated subsidiaries</td>
<td>22</td>
<td>—</td>
</tr>
<tr>
<td>Share of other comprehensive income of associates accounted for using equity method</td>
<td>6,154</td>
<td>4,225</td>
</tr>
<tr>
<td><strong>Total other comprehensive income (loss)</strong></td>
<td><strong>32,099</strong></td>
<td><strong>41,840</strong></td>
</tr>
<tr>
<td>Comprehensive income (loss)</td>
<td><strong>10,189</strong></td>
<td><strong>66,200</strong></td>
</tr>
</tbody>
</table>

Comprehensive income attributable to

- Comprehensive income attributable to owners of the parent
  - FY2013: 5,055
  - FY2014: 54,645
- Comprehensive income attributable to minority interests
  - FY2013: 5,134
  - FY2014: 11,555
## 6. Consolidated Statements of Cash Flows

<table>
<thead>
<tr>
<th>FY2013</th>
<th>FY2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 1, 2013 to March 31, 2014</td>
<td>April 1, 2014 to March 31, 2015</td>
</tr>
<tr>
<td><strong>Net income (loss) before income taxes and minority interests</strong></td>
<td><strong>35,840</strong></td>
</tr>
<tr>
<td><strong>Depreciation</strong></td>
<td><strong>45,767</strong></td>
</tr>
<tr>
<td><strong>Amortization of goodwill</strong></td>
<td><strong>2,484</strong></td>
</tr>
<tr>
<td><strong>Impairment loss</strong></td>
<td><strong>5,278</strong></td>
</tr>
<tr>
<td><strong>Increase(decrease) in net defined benefit liability</strong></td>
<td><strong>257</strong></td>
</tr>
<tr>
<td><strong>Decrease (increase) in net defined benefit asset</strong></td>
<td><strong>63</strong></td>
</tr>
<tr>
<td><strong>Increase (decrease) in allowance for doubtful accounts</strong></td>
<td><strong>52</strong></td>
</tr>
<tr>
<td><strong>Increase (decrease) in provision for repairs</strong></td>
<td><strong>1,803</strong></td>
</tr>
<tr>
<td><strong>Increase (decrease) in provision for environmental measures</strong></td>
<td><strong>657</strong></td>
</tr>
<tr>
<td><strong>Increase (decrease) in provision for business structure improvement</strong></td>
<td><strong>4,336</strong></td>
</tr>
<tr>
<td><strong>Interest and dividend income</strong></td>
<td><strong>9,118</strong></td>
</tr>
<tr>
<td><strong>Interest expenses</strong></td>
<td><strong>7,353</strong></td>
</tr>
<tr>
<td><strong>Share of (profit) loss of entities accounted for using equity method</strong></td>
<td><strong>73</strong></td>
</tr>
<tr>
<td><strong>Loss (gain) on sales of investment securities</strong></td>
<td><strong>2,001</strong></td>
</tr>
<tr>
<td><strong>Loss (gain) on valuation of investment securities</strong></td>
<td><strong>6</strong></td>
</tr>
<tr>
<td><strong>Loss on retirement of non-current assets</strong></td>
<td><strong>938</strong></td>
</tr>
<tr>
<td><strong>Loss (gain) on sales of non-current assets</strong></td>
<td><strong>111</strong></td>
</tr>
<tr>
<td><strong>Decrease (increase) in notes and accounts receivable - trade</strong></td>
<td><strong>5,782</strong></td>
</tr>
<tr>
<td><strong>Decrease (increase) in inventories</strong></td>
<td><strong>19,008</strong></td>
</tr>
<tr>
<td><strong>Increase (decrease) in notes and accounts payable - trade</strong></td>
<td><strong>59,995</strong></td>
</tr>
<tr>
<td><strong>Other, net</strong></td>
<td><strong>20,152</strong></td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td><strong>68,802</strong></td>
</tr>
<tr>
<td><strong>Interest and dividends income received</strong></td>
<td><strong>8,072</strong></td>
</tr>
<tr>
<td><strong>Interest expenses paid</strong></td>
<td><strong>7,542</strong></td>
</tr>
<tr>
<td><strong>Income taxes paid</strong></td>
<td><strong>11,045</strong></td>
</tr>
<tr>
<td><strong>Proceeds from insurance income on explosion and fire</strong></td>
<td><strong>-</strong></td>
</tr>
<tr>
<td><strong>I Net cash provided by (used in) operating activities</strong></td>
<td><strong>43,476</strong></td>
</tr>
<tr>
<td><strong>Purchase of property, plant and equipment</strong></td>
<td><strong>35,091</strong></td>
</tr>
<tr>
<td><strong>Proceeds from sales of property, plant and equipment</strong></td>
<td><strong>681</strong></td>
</tr>
<tr>
<td><strong>Purchase of intangible assets</strong></td>
<td><strong>2,385</strong></td>
</tr>
<tr>
<td><strong>Purchase of long-term prepaid expenses</strong></td>
<td><strong>685</strong></td>
</tr>
<tr>
<td><strong>Purchase of investment securities</strong></td>
<td><strong>3,245</strong></td>
</tr>
<tr>
<td><strong>Proceeds from sales and redemption of investment securities</strong></td>
<td><strong>7,499</strong></td>
</tr>
<tr>
<td><strong>Payments for transfer of business</strong></td>
<td><strong>-</strong></td>
</tr>
<tr>
<td><strong>Purchase of investments in subsidiaries resulting in change in scope of consolidation</strong></td>
<td><strong>2,238</strong></td>
</tr>
<tr>
<td><strong>Other, net</strong></td>
<td><strong>428</strong></td>
</tr>
<tr>
<td><strong>II Net cash provided by (used in) investing activities</strong></td>
<td><strong>(35,036)</strong></td>
</tr>
</tbody>
</table>

### Notes
- Millions of yen
<table>
<thead>
<tr>
<th></th>
<th>FY2013</th>
<th>FY2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net increase (decrease) in short-term loans payable</td>
<td>11,631</td>
<td>(3,896)</td>
</tr>
<tr>
<td>Increase (decrease) in commercial papers</td>
<td>-</td>
<td>(15,000)</td>
</tr>
<tr>
<td>Proceeds from long-term loans payable</td>
<td>112,317</td>
<td>31,318</td>
</tr>
<tr>
<td>Repayment of long-term loans payable</td>
<td>(54,022)</td>
<td>(41,400)</td>
</tr>
<tr>
<td>Proceeds from issuance of bonds</td>
<td>15,000</td>
<td>1,000</td>
</tr>
<tr>
<td>Redemption of bonds</td>
<td>(10,000)</td>
<td>(13,000)</td>
</tr>
<tr>
<td>Proceeds from stock issuance to minority shareholders</td>
<td>1,880</td>
<td>156</td>
</tr>
<tr>
<td>Proceeds from sales of treasury stock</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Purchase of treasury stock</td>
<td>(102)</td>
<td>(125)</td>
</tr>
<tr>
<td>Cash dividends paid</td>
<td>(6,009)</td>
<td>(2,002)</td>
</tr>
<tr>
<td>Cash dividends paid to minority shareholders</td>
<td>(3,700)</td>
<td>(3,552)</td>
</tr>
<tr>
<td>Other, net</td>
<td>(135)</td>
<td>(111)</td>
</tr>
<tr>
<td><strong>Ill Net cash provided by (used in) financing activities</strong></td>
<td><strong>66,868</strong></td>
<td><strong>(46,606)</strong></td>
</tr>
<tr>
<td>Effect of exchange rate change on cash and cash equivalents</td>
<td>5,735</td>
<td>2,767</td>
</tr>
<tr>
<td><strong>V Net increase (decrease) in cash and cash equivalents</strong></td>
<td><strong>26,298</strong></td>
<td><strong>(20,588)</strong></td>
</tr>
<tr>
<td><strong>VI Cash and cash equivalents at beginning of period</strong></td>
<td><strong>44,996</strong></td>
<td><strong>71,210</strong></td>
</tr>
<tr>
<td>Increase (decrease) in cash and cash equivalents resulting from change of scope of consolidation</td>
<td>(84)</td>
<td>-</td>
</tr>
<tr>
<td><strong>VII Cash and cash equivalents at end of period</strong></td>
<td><strong>71,210</strong></td>
<td><strong>50,622</strong></td>
</tr>
</tbody>
</table>
7. Segment Information

(1) Overview of Reportable Segments

The reportable segments of Mitsui Chemicals comprise those entities for which obtaining separate financial reports is possible and those are subject to regular review by the Board of Directors, which decides upon the distribution of management resources to said segments.

Mitsui Chemicals positions segments distinguished by their products and services within its headquarters. Each segment proposes comprehensive domestic and overseas strategies in addition to pursuing business expansion in its respective product and service area.

The six reportable segments (distinguished by products and services) that therefore comprise Mitsui Chemicals operations are: Functional Chemicals, Functional Polymeric Materials, Polyurethane, Basic Chemicals, Petrochemicals and Films and Sheets.

<table>
<thead>
<tr>
<th>Segments</th>
<th>Major Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Functional Chemicals</td>
<td>Healthcare materials, hygiene materials, specialty gas, catalysts, chemical products, agrochemical products and dental materials</td>
</tr>
<tr>
<td>Functional Polymeric Materials</td>
<td>Elastomers, performance compounds, specialty polyolefin</td>
</tr>
<tr>
<td>Polyurethane</td>
<td>Polyurethane materials, coating materials, adhesive materials, and molding materials</td>
</tr>
<tr>
<td>Basic Chemicals</td>
<td>Phenols, bisphenol-A, PTA, PET, ethylene oxide</td>
</tr>
<tr>
<td>Petrochemicals</td>
<td>Ethylene, propylene, polyethylene, polypropylene</td>
</tr>
<tr>
<td>Films and Sheets</td>
<td>Packaging films, electronic and optical films, and solar cell sheets</td>
</tr>
<tr>
<td>Others</td>
<td>Other related businesses, etc.</td>
</tr>
</tbody>
</table>

(2) Methods to Determine Net Sales, Income or Loss, Assets, and Others by Reportable Business Segment

Profit by reportable business segment is stated on an operating income basis. Intersegment net sales and transfers are based on the values of transactions undertaken between third parties.

(3) Information concerning Net Sales, Income or Loss, Assets, and Others by Reportable Business Segment

The previous fiscal year (April 1, 2013 – March 31, 2014)

<table>
<thead>
<tr>
<th>Reportable Segment</th>
<th>Functional Chemicals</th>
<th>Functional Polymeric Materials</th>
<th>Polyurethane</th>
<th>Basic Chemicals</th>
<th>Petrochemicals</th>
<th>Films and sheets</th>
<th>Total</th>
<th>Others (Note 1)</th>
<th>Sum total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1) To external customers</td>
<td>190,384</td>
<td>176,736</td>
<td>163,820</td>
<td>376,219</td>
<td>552,363</td>
<td>79,943</td>
<td>1,539,465</td>
<td>26,581</td>
<td>1,566,046</td>
</tr>
<tr>
<td>2) Internal sales among segments and transfers</td>
<td>5,172</td>
<td>18,780</td>
<td>3,413</td>
<td>30,264</td>
<td>160,479</td>
<td>2,609</td>
<td>220,717</td>
<td>59,432</td>
<td>280,149</td>
</tr>
<tr>
<td>Total</td>
<td>195,556</td>
<td>195,516</td>
<td>167,233</td>
<td>406,483</td>
<td>712,842</td>
<td>82,552</td>
<td>1,760,182</td>
<td>86,013</td>
<td>1,846,195</td>
</tr>
<tr>
<td>Segment income (loss)</td>
<td>14,994</td>
<td>11,901</td>
<td>(5,244)</td>
<td>(17,388)</td>
<td>25,350</td>
<td>877</td>
<td>30,490</td>
<td>(586)</td>
<td>29,904</td>
</tr>
<tr>
<td>Segment assets</td>
<td>333,111</td>
<td>166,414</td>
<td>125,390</td>
<td>188,509</td>
<td>410,934</td>
<td>84,166</td>
<td>1,308,524</td>
<td>22,190</td>
<td>1,330,714</td>
</tr>
<tr>
<td>Other items</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization (Note 2)</td>
<td>9,506</td>
<td>7,182</td>
<td>2,904</td>
<td>8,360</td>
<td>9,119</td>
<td>4,776</td>
<td>41,847</td>
<td>3,427</td>
<td>45,274</td>
</tr>
<tr>
<td>Amortization of goodwill</td>
<td>2,067</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>459</td>
<td>—</td>
<td>2,526</td>
<td>—</td>
<td>2,526</td>
</tr>
<tr>
<td>Amount invested in equity method affiliate</td>
<td>6,066</td>
<td>20,440</td>
<td>8,553</td>
<td>22,811</td>
<td>2,270</td>
<td>1,384</td>
<td>61,524</td>
<td>1,533</td>
<td>63,057</td>
</tr>
<tr>
<td>Capital expenditures (Note 2)</td>
<td>71,503</td>
<td>5,796</td>
<td>4,905</td>
<td>6,615</td>
<td>17,271</td>
<td>4,084</td>
<td>110,174</td>
<td>2,319</td>
<td>112,493</td>
</tr>
</tbody>
</table>

Notes:
1. “Others” category incorporates operations not included in reportable segments.
2. Depreciation and amortization, and capital expenditures include amortization costs and expenditures under long-term prepaid expenses.
The fiscal year under review (April 1, 2014 – March 31, 2015) (Millions of yen)

<table>
<thead>
<tr>
<th>Reportable Segment</th>
<th>Functional Chemicals</th>
<th>Functional Polymeric Materials</th>
<th>Polyurethane</th>
<th>Basic Chemicals</th>
<th>Petrochemicals</th>
<th>Films and sheets</th>
<th>Total (Note 1)</th>
<th>Sum total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1) To external customers</td>
<td>218,977</td>
<td>174,497</td>
<td>154,785</td>
<td>311,230</td>
<td>576,836</td>
<td>82,695</td>
<td>1,519,020</td>
<td>31,056</td>
</tr>
<tr>
<td>Internal sales among segments and transfers</td>
<td>4,245</td>
<td>20,237</td>
<td>3,090</td>
<td>30,909</td>
<td>145,284</td>
<td>3,196</td>
<td>206,961</td>
<td>61,801</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>223,222</td>
<td>194,734</td>
<td>157,875</td>
<td>342,139</td>
<td>722,120</td>
<td>85,891</td>
<td>1,725,981</td>
<td>92,857</td>
</tr>
<tr>
<td><strong>Segment income (loss)</strong></td>
<td>14,608</td>
<td>18,850</td>
<td>(3,544)</td>
<td>(7,368)</td>
<td>20,945</td>
<td>3,697</td>
<td>47,188</td>
<td>797</td>
</tr>
<tr>
<td><strong>Segment assets</strong></td>
<td>345,530</td>
<td>177,740</td>
<td>129,306</td>
<td>175,243</td>
<td>380,724</td>
<td>82,945</td>
<td>1,291,488</td>
<td>44,658</td>
</tr>
<tr>
<td><strong>Other items</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization (Note 2)</td>
<td>11,688</td>
<td>6,978</td>
<td>2,729</td>
<td>6,670</td>
<td>9,405</td>
<td>4,443</td>
<td>41,913</td>
<td>3,794</td>
</tr>
<tr>
<td>Amortization of goodwill</td>
<td>2,428</td>
<td>-</td>
<td>37</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,465</td>
<td>19</td>
</tr>
<tr>
<td>Amount invested in equity method affiliate</td>
<td>5,066</td>
<td>21,126</td>
<td>9,923</td>
<td>21,532</td>
<td>881</td>
<td>1,512</td>
<td>60,040</td>
<td>3,266</td>
</tr>
<tr>
<td>Capital expenditures (Note 2)</td>
<td>10,523</td>
<td>3,613</td>
<td>5,778</td>
<td>4,045</td>
<td>13,638</td>
<td>2,923</td>
<td>40,520</td>
<td>6,683</td>
</tr>
</tbody>
</table>

Notes: 1. "Others" category incorporates operations not included in reportable segments.
2. Depreciation and amortization, and capital expenditures include amortization costs and expenditures for long-term prepaid expenses.

(4) Reconciliation of Differences between Total Amounts of Reportable Segments and Consolidated Financial Statements (adjustment of difference) (Millions of yen)

<table>
<thead>
<tr>
<th>Net Sales</th>
<th>FY 2013</th>
<th>FY 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total reportable segment sales</td>
<td>1,760,182</td>
<td>1,725,981</td>
</tr>
<tr>
<td>Net sales classified under &quot;Others&quot;</td>
<td>86,013</td>
<td>92,857</td>
</tr>
<tr>
<td>Elimination of intersegment transactions</td>
<td>(280,149)</td>
<td>(268,762)</td>
</tr>
<tr>
<td>Net sales recorded in Consolidated Income Statements</td>
<td>1,566,046</td>
<td>1,550,076</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Income</th>
<th>FY 2013</th>
<th>FY 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total reportable segment income</td>
<td>30,490</td>
<td>47,188</td>
</tr>
<tr>
<td>Income classified under &quot;Others&quot;</td>
<td>(586)</td>
<td>797</td>
</tr>
<tr>
<td>Elimination of intersegment transactions and etc</td>
<td>(26)</td>
<td>(184)</td>
</tr>
<tr>
<td>Corporate expenses (note)</td>
<td>(4,979)</td>
<td>(5,761)</td>
</tr>
<tr>
<td>Operating income (loss) recorded in Consolidated Income Statements</td>
<td>24,899</td>
<td>42,040</td>
</tr>
</tbody>
</table>

Note: Corporate expenses mainly comprise general & administrative expenses which are usually not attributed to segments.

<table>
<thead>
<tr>
<th>Assets</th>
<th>FY 2013</th>
<th>FY 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total reportable segment assets</td>
<td>1,308,524</td>
<td>1,291,488</td>
</tr>
<tr>
<td>Assets classified under &quot;Others&quot;</td>
<td>82,945</td>
<td>44,658</td>
</tr>
<tr>
<td>Elimination of intersegment transactions</td>
<td>(67,855)</td>
<td>(91,512)</td>
</tr>
<tr>
<td>Corporate assets (note)</td>
<td>169,303</td>
<td>167,156</td>
</tr>
<tr>
<td>Assets recorded in Consolidated Balance Sheets</td>
<td>1,432,162</td>
<td>1,411,790</td>
</tr>
</tbody>
</table>

Note: Corporate assets are mainly attributed to the Company’s surplus management funds (cash and savings), long-term investment funds (investment securities), deferred tax assets and administrative departments.

<table>
<thead>
<tr>
<th>Other items</th>
<th>Reportable segments</th>
<th>Others</th>
<th>Adjustments (note)</th>
<th>Amounts from consolidated financial</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FY13</td>
<td>FY14</td>
<td>FY13</td>
<td>FY14</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>41,847</td>
<td>41,913</td>
<td>3,427</td>
<td>3,794</td>
</tr>
<tr>
<td>Amortization of goodwill</td>
<td>2,526</td>
<td>2,465</td>
<td>-</td>
<td>19</td>
</tr>
<tr>
<td>Investment in equity method affiliate</td>
<td>61,524</td>
<td>60,040</td>
<td>1,533</td>
<td>3,266</td>
</tr>
<tr>
<td>Capital expenditures</td>
<td>110,174</td>
<td>40,520</td>
<td>2,319</td>
<td>6,683</td>
</tr>
</tbody>
</table>

Note: Adjustments incorporate depreciation expenses, amortization expenses and capital expenditures which are related to R&D of new business.
8. Segment Related Information

Information by Region

The previous consolidated fiscal year (April 1, 2013 – March 31, 2014)
a. Net Sales

<table>
<thead>
<tr>
<th></th>
<th>Japan</th>
<th>China</th>
<th>Asia</th>
<th>America</th>
<th>Europe</th>
<th>Other regions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Sales (Millions of yen)</td>
<td>867,958</td>
<td>163,506</td>
<td>299,464</td>
<td>153,984</td>
<td>62,905</td>
<td>18,229</td>
<td>1,566,046</td>
</tr>
</tbody>
</table>

Notes:
1. Net sales are classified by country and region based on customer location.
2. Major countries and regions located in areas outside of Japan and China are as follows:
   (1) Asia: Taiwan, South Korea, Thailand, Malaysia, Singapore, India
   (2) America: The United States, Mexico
   (3) Europe: Germany, France
   (4) Other regions: Oceania, Africa

b. Tangible Assets

<table>
<thead>
<tr>
<th></th>
<th>Japan</th>
<th>Asia</th>
<th>Other regions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tangible Assets (Millions of yen)</td>
<td>341,187</td>
<td>67,046</td>
<td>17,607</td>
<td>425,840</td>
</tr>
</tbody>
</table>

Note:
Major countries and regions located in areas outside of Japan are as follows:
1. Asia: China, Taiwan, South Korea, Thailand, Malaysia, Singapore, India
2. Other regions: North America, Europe

The consolidated fiscal year under review (April 1, 2014 – March 31, 2015)
a. Net Sales

<table>
<thead>
<tr>
<th></th>
<th>Japan</th>
<th>China</th>
<th>Asia</th>
<th>America</th>
<th>Europe</th>
<th>Other regions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Sales (Millions of yen)</td>
<td>863,966</td>
<td>165,459</td>
<td>265,487</td>
<td>166,400</td>
<td>74,273</td>
<td>14,491</td>
<td>1,550,076</td>
</tr>
</tbody>
</table>

Notes:
1. Net sales are classified by country and region based on customer location.
2. Major countries and regions located in areas outside of Japan and China are as follows:
   (1) Asia: Taiwan, South Korea, Thailand, Malaysia, Singapore, India
   (2) America: The United States, Mexico
   (3) Europe: Germany, France
   (4) Other regions: Oceania, Africa

b. Tangible Assets

<table>
<thead>
<tr>
<th></th>
<th>Japan</th>
<th>Singapore</th>
<th>Asia</th>
<th>Other regions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tangible Assets (Millions of yen)</td>
<td>332,554</td>
<td>45,748</td>
<td>33,399</td>
<td>21,928</td>
<td>433,629</td>
</tr>
</tbody>
</table>

Note:
Major countries and regions located in areas outside of Japan and Singapore are as follows:
1. Asia: China, Taiwan, South Korea, Thailand, Malaysia, India
2. Other regions: North America, Europe

Information Concerning Impairment Loss of Fixed Assets by Reportable Segment

The previous consolidated fiscal year (April 1, 2013 – March 31, 2014)

<table>
<thead>
<tr>
<th></th>
<th>Functional Chemicals</th>
<th>Functional Polymeric Materials</th>
<th>Polyurethane</th>
<th>Basic Chemicals</th>
<th>Petrochemicals</th>
<th>Films and sheets</th>
<th>Others</th>
<th>Corporate Expenses</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impairment loss</td>
<td>1,557</td>
<td>26</td>
<td>6,835</td>
<td>5,849</td>
<td>1,934</td>
<td>530</td>
<td>148</td>
<td></td>
<td>16,879</td>
</tr>
</tbody>
</table>

The consolidated fiscal year under review (April 1, 2014 – March 31, 2015)

<table>
<thead>
<tr>
<th></th>
<th>Functional Chemicals</th>
<th>Functional Polymeric Materials</th>
<th>Polyurethane</th>
<th>Basic Chemicals</th>
<th>Petrochemicals</th>
<th>Films and sheets</th>
<th>Others</th>
<th>Corporate Expenses</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impairment loss</td>
<td>68</td>
<td>138</td>
<td>1,677</td>
<td>1,973</td>
<td>18</td>
<td>952</td>
<td>452</td>
<td></td>
<td>5,278</td>
</tr>
</tbody>
</table>
### Information Concerning the Amount of Amortization and Unamortized Balance of Goodwill by Reportable Segment

The previous consolidated fiscal year (April 1, 2013 – March 31, 2014)

(Millions of yen)

<table>
<thead>
<tr>
<th>Segment</th>
<th>Functional Chemicals</th>
<th>Functional Polymeric Materials</th>
<th>Polyurethane</th>
<th>Basic Chemicals</th>
<th>Petrochemicals</th>
<th>Films and sheets</th>
<th>Others</th>
<th>Corporate Expenses</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount of amortization</td>
<td>2,067</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>459</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,526</td>
</tr>
<tr>
<td>Unamortized balance</td>
<td>34,771</td>
<td>-</td>
<td>187</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>34,958</td>
</tr>
</tbody>
</table>

The consolidated fiscal year under review (April 1, 2014 – March 31, 2015)

(Millions of yen)

<table>
<thead>
<tr>
<th>Segment</th>
<th>Functional Chemicals</th>
<th>Functional Polymeric Materials</th>
<th>Polyurethane</th>
<th>Basic Chemicals</th>
<th>Petrochemicals</th>
<th>Films and sheets</th>
<th>Others</th>
<th>Corporate Expenses</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount of amortization</td>
<td>2,428</td>
<td>-</td>
<td>37</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>19</td>
<td>2,484</td>
</tr>
<tr>
<td>Unamortized balance</td>
<td>34,299</td>
<td>-</td>
<td>167</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>512</td>
<td>34,978</td>
</tr>
</tbody>
</table>

### Information Concerning the Amount of Amortization and Unamortized Balance of Negative Goodwill by Reportable Segment

The previous consolidated fiscal year (April 1, 2013 – March 31, 2014)

(Millions of yen)

<table>
<thead>
<tr>
<th>Segment</th>
<th>Functional Chemicals</th>
<th>Functional Polymeric Materials</th>
<th>Polyurethane</th>
<th>Basic Chemicals</th>
<th>Petrochemicals</th>
<th>Films and sheets</th>
<th>Others</th>
<th>Corporate Expenses</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount of amortization</td>
<td>88</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>591</td>
<td>-</td>
<td>-</td>
<td>679</td>
</tr>
<tr>
<td>Unamortized balance</td>
<td>23</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>23</td>
</tr>
</tbody>
</table>

The consolidated fiscal year under review (April 1, 2014 – March 31, 2015)

(Millions of yen)

<table>
<thead>
<tr>
<th>Segment</th>
<th>Functional Chemicals</th>
<th>Functional Polymeric Materials</th>
<th>Polyurethane</th>
<th>Basic Chemicals</th>
<th>Petrochemicals</th>
<th>Films and sheets</th>
<th>Others</th>
<th>Corporate Expenses</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount of amortization</td>
<td>23</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>23</td>
</tr>
<tr>
<td>Unamortized balance</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>